Horita Nobuyuki, Hashimoto Satoru, Miyazawa Naoki, Fujita Hiroyuki, Kojima Ryota, Inoue Miyo, Ueda Atsuhisa, Ishigatsubo Yoshiaki I, Kaneko Takeshi
Intern Med. 2015;54(12):1473-9. doi: 10.2169/internalmedicine.54.4015.
The impact of corticosteroids on acute respiratory distress syndrome (ARDS) mortality remains controversial following the publication of numerous trials, observational studies and meta-analyses. An updated meta-analysis is warranted, as a few original studies on this topic have been published since the last meta-analysis.
We searched for eligible articles using four databases. In particular, we included full-length original articles providing sufficient data for evaluating the impact of corticosteroid treatment on adult ARDS mortality in the form of odds ratios. A fixed model with the confidence interval method was used. An assessment of publication bias and sensitivity analyses were also conducted.
We included 11 of 185 articles. The pooled odds ratio for corticosteroids with respect to all-cause mortality involving 949 patients was 0.77 [95% confidence interval (CI): 0.58-1.03, p=0.079] with strong heterogeneity(I2=70%, p<0.001). The results of the sensitivity analysis, Begg-Kendall test (τ=0.53, p=0.024)and funnel plot consistently suggested the existence of strong publication bias. After six potentially unpublished cohorts were filled using Duval's trim and fill method, the pooled odds ratio shifted to 1.11 (95% CI0.86-1.44, p=0.427). In addition, the sensitivity analyses suggested that corticosteroid treatment has a different impact on mortality depending on the comorbidities and trigger events.
We were unable to confirm, based on the data of published studies, the favorable impact of corticosteroid therapy on mortality in overall ARDS cases. Published articles exhibit strong publication bias,and previous meta-analyses may be affected by this publication bias. Further research focusing on pathophysiology- or trigger event-specific ARDS is anticipated.
在众多试验、观察性研究和荟萃分析发表之后,皮质类固醇对急性呼吸窘迫综合征(ARDS)死亡率的影响仍存在争议。鉴于自上次荟萃分析以来已发表了一些关于该主题的原始研究,因此有必要进行更新的荟萃分析。
我们使用四个数据库搜索符合条件的文章。具体而言,我们纳入了提供足够数据以评估皮质类固醇治疗对成人ARDS死亡率影响的全文原始文章,数据形式为比值比。使用置信区间法的固定模型。还进行了发表偏倚评估和敏感性分析。
我们纳入了185篇文章中的11篇。涉及949例患者的皮质类固醇全因死亡率的合并比值比为0.77 [95%置信区间(CI):0.58 - 1.03,p = 0.079],具有很强的异质性(I2 = 70%,p < 0.001)。敏感性分析结果、Begg-Kendall检验(τ = 0.53,p = 0.024)和漏斗图一致表明存在很强的发表偏倚。使用Duval的修剪和填充方法填补六个可能未发表的队列后,合并比值比变为1.11(95% CI 0.86 - 1.44,p = 0.427)。此外,敏感性分析表明,皮质类固醇治疗对死亡率的影响因合并症和触发事件而异。
基于已发表研究的数据,我们无法证实皮质类固醇治疗对总体ARDS病例死亡率的有利影响。已发表的文章存在很强的发表偏倚,先前的荟萃分析可能受到这种发表偏倚的影响。预计将开展针对特定病理生理学或触发事件的ARDS的进一步研究。